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Abstract  
Objective. Platelets are increasingly implicated in processes beyond hemostasis and 
thrombosis, such as vascular remodeling. Members of the matrix metalloproteinase 
(MMP) family not only remodel the extracellular matrix but also modulate platelet 
function. Here we made a systematic comparison of the roles of MMP family 
members in acute thrombus formation under flow conditions and assessed platelet-
dependent collagenolytic activity over time. Approach and Results. 
Pharmacological inhibition of MMP-1 or -2 (human) or deficiency in MMP-2 (mouse) 
suppressed collagen-dependent platelet activation and thrombus formation under 
flow, whereas MMP-9 inhibition/deficiency stimulated these processes. Absence of 
MMP-3 was without effect. Interestingly, MMP-14 inhibition led to the formation of 
larger thrombi, which occurred independently of its capacity to activate MMP-2. 
Platelet thrombi exerted local collagenolytic activity capable of cleaving immobilized 
dye-quenched collagen and fibrillar collagen fibers within hours, with loss of the 
majority of the platelet adhesive properties of collagen as a consequence. This 
collagenolytic activity was redundantly mediated by platelet-associated MMP-1, -2, -9 
and -14 but occurred independently of platelet α-granule release (Nbeal2-/- mice). 
The latter was in line with subcellular localization experiments, which indicated a 
granular distribution of MMP-1 and -2 in platelets, distinct from α-granules. Whereas 
MMP-9 protein could not be detected inside platelets, activated platelets did bind 
plasma-derived MMP-9 to their plasma membrane. Overall platelet MMP activity was 
predominantly membrane-associated and influenced by platelet activation status. 
Conclusion. Platelet-associated MMP-1, -2, -9, and -14 differentially modulate acute 
thrombus formation and at later time points limit thrombus formation by exerting 
collagenolytic activity. 
 
 
 
 
Nonstandard Abbrevations and Acronyms  
MMP   matrix metalloproteinase 
PS  phosphatidylserine 
Cvx  convulxin 
PAR  protease activated receptor 
GPVI  glycoprotein VI 
DQ  dye quenched 
WT  wild type 
SAC  surface area coverage 
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Introduction 
The last decades progress has been made in obtaining insight into the molecular 
mechanisms underlying platelet adhesion to exposed extracellular matrix 
components, platelet activation and subsequent thrombus formation.1 It is proposed 
that platelet function is modulated by members of the matrix metalloproteinase 
(MMP) family.2 MMPs are found in most vascular cells, including platelets, and in 
plasma. It has been demonstrated that the MMP-2 concentration in arterial blood 
from patients with acute coronary syndrome and in shed blood from a skin wound 
correlates with platelet activation and platelet number3, 4, which suggests that platelet 
MMPs can contribute considerably to total plasma MMP levels. Platelets contain 
MMP-1 (not in mouse), -2, -3 and -14.5-7 Over the last years the presence of relevant 
levels of MMP-9 in platelets has been a matter of extensive debate.8-11 The classical 
view in cell biology is that MMP-14, also called membrane type 1 MMP (MT1-MMP), 
is membrane-inserted and that MMP-1, -2 and -9 become secreted upon cell 
activation. However, there are clear indications that MMP-1, -2 but also MMP-9 can 
interact and associate with the surface of platelets.3, 5, 12-15 Although MMP-1 and -3 
seem to be mainly present in platelet α-granules16, conflicting evidence exists on the 
storage and release of platelet MMP-2, since it has been found in both the α-
granules16 and the cytoplasm.12 The recent discovery that mutations in NBEAL2 
underlie an inherited bleeding disorder characterized by a lack of α-granules within 
platelets (gray platelet syndrome), combined with the generation of Nbeal2-/- mice17 
provides a means to investigate the subcellular localization and role of MMP family 
members in more detail. Most MMPs are produced in a latent pro-MMP form which 
can be enzymatically activated upon platelet activation. For instance, platelet MMP-
14 activates MMP-2 on the platelet surface presumably by forming a complex with 
tissue inhibitor of metalloproteinases-2 (TIMP-2).5 Ample evidence exists that 
recombinant MMP-115, 18 and -212, 13, 19-21 potentiate adhesion or aggregation of 
human washed platelets or platelet-rich plasma in vitro, whereas MMP-9 exhibits an 
inhibitory effect.6, 13, 21, 22 Less well studied is the role of these MMP family members 
in platelet activation under physiological whole blood flow conditions. So far, only for 
MMP-2 a role in in vivo thrombus formation has been reported.23 In addition, even 
less is known about possible roles of MMP-3 and -14 in platelet activation.  
In addition to their proposed effects on platelet function, MMPs are important 
in the physiological turnover and pathophysiological remodeling of the extracellular 
matrix. These vascular actions have been confined especially to the collagenase 
(MMP-1, -8, -13) and gelatinase (MMP-2 and -9) classes of MMPs that have, 
respectively, interstitial collagens I, II and III, and denatured collagens as major 
substrates.24 Although the collagenolytic activity of platelets has already been 
described in 197425, it is unclear which platelet-associated MMP family members 
exert this activity. We hypothesize that proteolytically active MMPs associate with 
platelets locally at the site of injury, where they can act on both thrombus formation 
and underlying matrix components. For the present study a systematic comparison 
was made of the roles of different MMP family members on platelet activation and 
thrombus formation under physiological arterial flow conditions, using an established 
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flow chamber model.26 Furthermore, platelet-collagenolytic activity was assessed 
over time using three different substrates in the presence of MMP-specific inhibitors.  
 
Materials and Methods 
Materials and Methods are available in the online-only Data Supplement.  
 
Results   
Differential modulating effects of MMPs on platelet activation and thrombus 
formation under arterial flow conditions. 
Human whole blood pre-incubated with MMP-specific inhibitors or blood from mice 
deficient in MMP-2, -3, -9 was perfused over a fibrillar type I collagen surface at a 
vWF-dependent shear rate of 1000 s-1 to systematically compare the roles of these 
MMPs on platelet activation and thrombus formation. Pharmacological inhibition of 
MMP-1 or MMP-2 resulted in significantly diminished platelet activation and surface 
area covered with platelets, while MMP-9 or -14 inhibition promoted these processes 
(figure 1A-B). Strikingly, inhibition of the membrane-inserted MMP-14 led to the 
formation of fewer but larger thrombi (figure 2), which appeared to be more stable in 
time (visual inspection during real-time microscopic monitoring). Interestingly, MMP-9 
inhibition appeared to be without significant effect on thrombus size (P=0.37), 
whereas platelet spreading was increased (visual inspection during real-time 
microscopic monitoring). No additive effect of combined MMP-9 and -14 inhibition 
was found on thrombus size when compared to single inhibition of MMP-14 (figure 
2). This suggests that the action mechanisms by which MMP-9 and -14 potentiate 
platelet activation and/or thrombus formation may differ. 
 Similar to the findings in human blood, absence of MMP-2 and -9 in the 
murine system had an opposing effect. Thrombi formed with blood from Mmp2-/- mice 
tended to be smaller (not shown) than wild type thrombi and were less active as P-
selectin expression (CD62P, marker for platelet secretion) and PS exposure (marker 
for platelet procoagulant activity) were significantly reduced (P<0.05) (figure 1C). In 
contrast, perfusion of blood from Mmp9-/- mice resulted in thrombi that covered an 
increased surface area (+39%, P=0.04). This was accompanied by higher levels of 
PS exposure (+42%, P=0.04) and P-selectin expression (+83%, P=0.33) compared 
to corresponding wild type mice. Deficiency of MMP-3 had no effect on platelet 
activation and thrombus formation (figure 1C) and this MMP family member was 
therefore not included in further experiments. Of note, the roles of MMP-1 and -14 
could not be investigated in the murine system as murine platelets do not express 
MMP-1 and MMP-14 deficient mice suffer from postnatal lethality.27 
Based on their modulating effect on platelet activation and thrombus 
formation, we next investigated whether MMP-1, -2, -9 and -14 localize on the 
thrombus surface. Using fluorescently labeled MMP antibodies, we found that MMP-
1, -2, -9 and -14 all associate with the membrane of a human platelet thrombus. 
Addition of isotype-matched control antibodies yielded no detectable levels of 
fluorescence (figure 3). MMP-1, -2 and -9 associated with the thrombus in a speckled 
 5 
manner, whereas the membrane type MMP-14 appeared to be homogeneously 
distributed over the thrombus (figure 3).  
 
GPVI-activated platelets rapidly display high MMP activity on their surface. 
Currently, it is unclear how platelet MMP activity is triggered, as well as its relevance 
compared to other sources of MMP activity. Here, we used an OmniMMP fluorogenic 
substrate to measure platelet-derived MMP activity (membrane bound and/or 
secreted) from washed platelets after platelet stimulation with weak (thrombin, 2-
MeSADP, thapsigargin) or strong (convulxin, ionomycin) Ca2+ mobilizing agents.28 
Interestingly, activation with ionomycin and the GPVI receptor agonist convulxin 
(whether or not in combination with thrombin) triggered the highest levels of 
fluorescent MMP substrate conversion, with a 9.6-fold and 5.2-fold increase, 
respectively, compared to resting platelets (figure 4A). Stimulation with the weak Ca2+ 
inducing agents showed a trend towards increased MMP activity, although this was 
not statistically significant. MMP activity was completely inhibited by the general 
MMP inhibitor phenanthroline (figure 4A), but not by the cysteine, serine and 
threonine protease inhibitor leupeptin (10.7 μg/mL, n=5), confirming selectivity of the 
OmniMMP assay for MMPs. A ten-fold dilution of plasma treated with 4-amino-phenyl 
mercuric acetate (activating latent MMPs) yielded an MMP activity of 8.5 μg/mL 
(n=7), which was comparable to GPVI-stimulated platelets (9.4 μg/mL). 
Following our findings that MMP-1, -2, -9 and -14 can associate with the 
thrombus surface (figure 3) and GPVI agonists being the most potent trigger of 
platelet MMP activity, we next assessed the subcellular localization of these MMP 
family members in platelets using confocal microscopy. In resting platelets, MMP-1 
and -2 displayed a granular distribution, without significant overlap with the α-granule 
marker P-selectin (Pearson’s correlation co-efficient of 0.24 for MMP-1 and 0.11 for 
MMP-2, suppl. fig. I-II). Upon platelet activation with convulxin, MMP-1 and -2 
relocated to the platelet plasma membrane (suppl. figure I). The membrane-type 
MMP-14 localized on the plasma membrane of both resting and activated platelets. 
Interestingly, we observed caps with high levels of MMP-14 fluorescence on the 
plasma membrane of activated platelets, possibly suggestive of clustering of MMP 
activity. In line with the most recent literature9, 29, we could not detect MMP-9 in 
resting or activated platelets. Interestingly though, activated platelets did bind 
plasma-derived MMP-9 within 5 minutes after their activation (suppl. figure III), which 
likely accounts for the MMP-9 binding to thrombi observed in figure 3. 
 Given our data that activated platelets rapidly accumulate MMPs on their 
surface, we next measured the MMP activity of the platelet membrane fraction in 
comparison to the supernatant of (non-)activated platelets. The vast majority of MMP 
activity after GPVI stimulation was indeed membrane-bound (11.3 μg/mL), compared 
to 0.5 μg/mL in the supernatant (figure 4B). Kinetic experiments indicated that 
OmniMMP activity rapidly increased after platelet activation and reached a maximum 
slope of 37 FU/min 10 minutes after activation, after which MMP activity slowly 
declined (figure 4C). Knowing that MMP-2 is reported to be activated on the platelet 
plasma membrane5, we specifically measured MMP-2 activity using a cell-based 
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MMP-2 activity assay with  a reported sensitivity for MMP-2 in the nanomolar range. 
Platelet activation with convulxin led to a rapid increase in platelet-bound MMP-2 
activity with maximal activity of 1.6 FU/min reached within 5 minutes after activation. 
Pre-incubation with MMP-2 inhibitor III completely inhibited MMP-2 activity (figure 
4D). In sum, our data suggest that platelets can rapidly display high levels of MMP 
activity on their membrane. This activity is dependent on platelet stimulation by 
strong, high cytosolic Ca2+ mobilizing agents such as the GPVI receptor agonist 
convulxin.  
 
MMP-dependent collagen degradation is localized at the site of the thrombus 
and affected by platelet activation status. 
Given the presence of MMP activity on the membrane of activated platelets, we next 
investigated the collagen matrix degrading potential of platelet thrombi. Therefore, 
thrombi were formed ex vivo in a flow device on a combined surface of DQ collagen 
(homogeneous coating on surface) and Horm collagen (fibrillar coating) at arterial 
shear rate. Plasma and unbound cells were removed by careful rinsing. An absence 
of white blood cells was confirmed by CD45 staining (not shown). Within 1.5 h after 
thrombus formation fluorescent signals were detected due to cleavage of DQ 
collagen locally at the site of the thrombi, indicating collagenolytic activity, which was 
predominantly present at the thrombus core (figure 5A). Similar patterns of thrombus-
related fluorescence were obtained when DQ gelatin was used instead of DQ 
collagen (data not shown). Interestingly, upon post-addition of thrombin, thrombus 
collagenolytic activity was predominantly detected at the thrombus shell of both 
human and murine thrombi (DQ collagen fluorescence pattern in figure 5C). 
Collagenolytic activity was also found on the fibrillar Horm collagen fibers and 
platelet-membrane tethers, which was most prominent after post-stimulation with 
thrombin (representative fluorescence images figure 5C). Post-addition of 
phenantroline immediately after the thrombi were formed led to an almost complete 
suppression of DQ collagen fluorescence (figure 5A-B). Post-addition of MMP-
specific inhibitors, resulted in a significant suppression of DQ collagen fluorescence 
of 40-60% depending on the inhibitor used (figure 5B). The comparable effects found 
with the different MMP-specific inhibitors, suggest a redundancy in the collagenolytic 
capacity of platelet MMP-1, -2, -9 and -14. A similar reduced thrombus-dependent 
collagenolytic activity was observed with thrombi made from WT, Mmp2-/- or Mmp9-/- 
blood (figure 5C-D). Interestingly, no difference was observed with Nbeal2-/- thrombi, 
indicating that thrombus-dependent collagenolytic activity is not mediated via α-
granule release (figure 5D). This fits with our data that platelet-MMPs are 
predominantly localized outside platelet α-granules (suppl. fig. I). 
 Alternatively, thrombus-dependent degradation of fibrillar type I collagen was 
visualized over time using scanning electron microscopy. Type I collagen fibers 
became visibly thinner within 3 h of incubation with thrombi, started to fragment at 4 h 
and were nearly completely cleared after 17 h. Adherent and spread platelets were 
still present at the site of the thrombus (figure 6). This process was dependent on 
MMP activity as addition of phenanthroline prevented degradation of collagen by 
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75% (supplemental figure IV). To investigate the ability of platelet-degraded collagen 
to sustain platelet deposition pre-formed thrombi (T=0 h) were incubated with HEPES 
buffer supplemented with 2-MeSADP/thrombin for 6 h and then rinsed. Freshly taken 
DiOC6-labeled whole blood was then flowed over the same surface for 4 minutes. 
Whereas initial thrombus surface area coverage was 22.2 ± 4.5% (T=0h); surface 
area covered by fresh DiOC6-labeled blood was greatly reduced to 1.5 ± 0.7% 
(P<0.001), indicating a loss of platelet-adhesive properties of platelet-degraded 
collagen (suppl. figure V). Of note, labeling with the membrane probe DiOC6 did not 
affect platelet adhesive capacity (not shown). In sum, these results show that 
platelet-associated MMP family members are capable of locally degrading an 
immobilized collagen matrix in a redundant manner, thereby restricting future 
thrombus formation in vitro. 
 
Discussion  
This study demonstrates, for the first time, that platelet-associated MMP-1, -2, -9 and 
-14 play a dual role in collagen-dependent thrombus formation. They directly 
modulate platelet activation and thrombus formation under flow, and are capable of 
degrading the underlying collagen matrix, thereby restricting future thrombus 
formation.  
By employing the established multiparameter flow chamber assay26, we made 
a systematic comparison of the role of different MMP family members in whole blood 
platelet activation and thrombus formation under arterial flow conditions. 
Interestingly, whereas MMP-1 and -2 enhance, MMP-9 and -14 inhibit platelet P-
selectin expression (marker for platelet secretion), platelet procoagulant activity and 
thrombus formation. Deficiency in MMP-3 was without effect on these parameters, 
which is in line with a report that similarly found no effect of MMP-3 inhibition on 
platelet aggregation in the human system.18 Our results regarding the stimulatory 
function of MMP-1 and -2 extend the finding that MMP-1 can bind to platelet β3 
thereby priming platelets for aggregation18 and that MMP-2 is involved in the 
modification of platelet glycoprotein Ib-V-IX and αIIbβ3 resulting in enhanced platelet 
adhesion and aggregation.14, 22 MMP-1 has also been reported to cleave the N-
terminal exodomain of the thrombin receptor PAR-1, resulting in a tethered ligand 
that activates G-protein-coupled receptor pathways in platelets.15 However, this 
manuscript received no follow-up in literature so far. 
The thrombus inhibiting effects of MMP-9 and MMP-14 appear to be more 
potent than the stimulatory effects of MMP-1 and -2. We propose that MMP-9 
interferes with platelet adhesive properties since we observed increased platelet 
spreading and surface area covered by thrombi upon MMP-9 inhibition, while 
thrombus size was comparable to the vehicle control. Cleavage of platelet CD40L by 
MMP-930, 31 may affect thrombus stability at a later stage.32 In contrast, MMP-14 was 
shown to primarily limit thrombus growth and stabilization as both the surface area 
coverage and the thrombus size were increased in the presence of the MMP-14 
inhibitor. The employed pharmacological inhibitor of MMP-14 (NSC-405020) does not 
interfere with the capacity to activate MMP-233, suggesting that other targets for 
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MMP-14 on the platelet surface may exist. As NSC-405020 directly interacts with the 
hemopexin domain of MMP-14, possible targets for MMP-14 could be linked to the 
homodimerization of MMP-14 or its collagenolytic activity.33 
Our observation that MMP-1, -2, -9 and -14 associate with thrombi formed on 
collagen under flow was substantiated by our finding that MMP-1 and -2 rapidly 
relocate from granule structures inside the platelet to the plasma membrane of 
activated platelets. The membrane-type MMP-14 localized on the plasma membrane 
of both unstimulated and activated platelets. Although we could not detect MMP-9 
protein in resting or activated platelets, we did observe that activated platelets bind 
plasma-derived MMP-9, which likely accounts for the MMP-9 binding to thrombi 
observed in figure 3. Based on our findings it is tempting to conclude that MMP-9 is 
most likely absent or present in neglectable amounts in platelets. However, given the 
persistent debate in literature on this topic we decided to perform an extensive 
literature search and found 26 original research reports in which the presence of 
MMP-9 was examined in human, mouse or rat platelets. Interestingly, in 11 out of 26 
reports MMP-9 was detected in platelets, whereas in the other 15 reports it remained 
undetectable (Suppl. Table I). We here summarize key underlying reasons for this 
discrepancy and provide several recommendations for future studies and reporting 
findings: I) Platelet MMP-9 levels might be below the detection limit of some of the 
assays used. It is therefore of importance that authors state both the detection limit of 
their assay as well as the final sample concentration; II) Buffers containing EDTA or 
sodium orthovanadate (Na3VO4) have inhibitory effects on MMP activity and should 
be avoided when determining MMP-9 activity using zymography11; III) Potential 
contamination of the platelet sample with CD45+ leucocytes could lead to a false 
positive signal as CD45+ leucocytes contain considerable levels of MMP-9.9, 29 
Analysis of the purity of the platelet sample (e.g. by flow cytometry) is thus highly 
recommended; V) When detecting platelet MMP-9 levels in a plasma environment it 
should be taken into account that plasma MMP-9 can bind to activated platelets (this 
manuscript). In line with this finding, platelet pre-activation during blood drawing and 
sample preparation should be minimized to avoid plasma MMP-9 binding to the 
platelet plasma membrane. 
We demonstrate that MMPs not only accumulate on the platelet plasma 
membrane but also display MMP activity. Platelet MMP activity was highest after 
stimulation with strong high calcium-mobilizing agents, such the platelet collagen 
GPVI receptor agonist convulxin, and reached a maximal activity after 5-10 minutes 
of activation (MMP-2 and OmniMMP substrate, respectively). At first sight our 
findings may challenge reports showing that platelet-derived MMP activity after 
collagen stimulation is mainly confined to the supernatant21 and not the platelet-
membrane fraction.5, 15 However, others that demonstrated release of MMP-2 and -9, 
simultaneously also showed the association of these MMP family members with the 
platelet surface.6, 13, 14, 18, 23 In addition, Chesney et al.25 found that collagenase 
exhibits its highest activity in the platelet membrane fraction, which is in line with our 
findings. We postulate that non-uniformity in the use of platelet agonists and in the 
definition of platelet supernatant may explain part of the discrepancies in literature 
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regarding platelet-derived MMP activity. In our hands, agonists evoking sustained 
high cytosolic Ca2+ levels, such as collagen, are strong inducers of platelet-exposed 
MMP activity. Additionally, here we define supernatant as the fraction that is secreted 
from (non-)activated platelets, i.e. the platelet releasate. This differs from the study 
by Trivedi et al.15 in which supernatant is referred to as the lysate of centrifugated 
(non-)activated platelet pellet. In this case it is expected that the actual platelet 
releasate is lost during the procedure and is only a fraction of the “supernatant”.15 
Next, we investigated a potential physiological role for platelet-membrane 
associated MMP activity and found that in vitro-formed thrombi effectively cleave 
immobilized dye-quenched collagen or degraded fibrillar type I collagen within hours 
after formation. This led to a marked restriction of future thrombus formation in vitro. 
Hereby our findings add to emerging knowledge on the existence and nature of 
persistent thrombus activities.34 Interestingly, the core of the thrombus appeared to 
be most active in cleaving dye-quenched collagen. However, upon post-addition of 
thrombin the thrombus-mediated MMP activity was predominantly present at the 
outer shell of the thrombi. Platelet-associated MMP-1, -2, -9 and -14 (human/mouse) 
mediated this collagenolytic activity in a redundant manner. An absence of platelet α-
granules (Nbeal2-/-) did not affect thrombus-mediated collagenolytic activity, which fits 
with our observation that subcellular localization of MMP-1, -2 and -14 does not 
significantly overlap with the α-granule constituent P-selectin. Hereby our data shed 
new light on the contrasting findings reported in literature regarding proposed 
colocalization of MMP-1 and -2 with α-granules.12, 16  
 In sum, we show that MMP-1 and -2 stimulate platelet activation and thrombus 
formation under arterial flow, whereas MMP-9 and -14 act inhibitory on these 
processes. Secondly, we demonstrate that the membrane fraction of collagen-
stimulated platelets exerts high levels of collagenolytic activity, which leads to 
localized degradation of immobilized collagen fibers and restriction of future 
thrombus formation. Platelet-associated MMP-1, -2, -9 and -14 have redundant roles 
herein.  
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Significance 
This study demonstrates, for the first time, that platelet-associated MMP-1, -2, -9 and 
-14 play a dual role in collagen-dependent thrombus formation. We show that MMP-1 
and -2 stimulate platelet activation and thrombus formation under arterial flow, 
whereas MMP-9 and -14 act inhibitory on these processes. In addition, we 
demonstrate that the membrane fraction of collagen-stimulated platelets exerts high 
levels of collagenolytic activity, which leads to localized degradation of immobilized 
collagen fibers and restriction of future thrombus formation. Platelet-associated 
MMP-1, -2, -9 and -14 have redundant roles herein. We hypothesize that this 
localized matrix degradation could result in increased accessibility for blood cells to 
infiltrate into the underlying matrix. This provides a novel and highly relevant 
mechanism in which can be intervened to prevent pathological matrix remodeling, 
thrombosis or bleeding.  
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Figure Legends 
 
Figure 1. MMP-1 and -2 promote collagen-dependent platelet activation and 
thrombus formation under flow whereas MMP-9 and -14 suppress these 
processes. Blood from healthy human controls was pre-incubated with inhibitors of 
MMP-1/8 (FN439), MMP-2 (MMP-2 inhibitor III), MMP-9 (MMP-9 inhibitor I) and 
MMP-14 (NSC-405020) for 10 min (A-B). Alternatively, murine blood from Mmp2, 3, 
or 9 deficient mice or matched wild types was used (C). Blood was perfused over 
immobilized Horm collagen at a shear rate of 1000 s-1 for 4 min. Formed thrombi 
were stained for PS exposure and CD62P expression by post-perfusion with AF647-
annexin A5 and FITC-labeled αCD62P mAb respectively. (A) Representative phase 
contrast and fluorescence images of human thrombi pre-treated with MMP-specific 
inhibitors. (B) Bar graphs represent analysis of surface area coverage of human 
(labeled) thrombi pre-treated with MMP-specific inhibitors. (C) Bar graphs represent 
analysis of surface area coverage of (labeled) Mmp2, 3 or 9 deficient murine thrombi. 
Scale bar= 50 μm, data are mean ± SEM (n=4-7); *P<0.05, **P<0.01. 
Figure 2. Inhibition of human MMP family members differentially affects 
thrombus size under flow. Thrombi were formed as described for figure 1. Bar 
graph represents thrombus size, expressed as integrated feature size. Data are 
mean ± SEM (n=4-7); *P<0.05, **P<0.01. 
Figure 3. Human MMP-1, -2, -9 and -14 are localized on the thrombus surface. 
Human blood was perfused over immobilized collagen at a shear rate of 1000 s-1 for 
4 min. Formed thrombi on coverslips were rinsed with HEPES buffer and post-
stained for MMP-1, -2, -9 by single step conjugated mAbs. MMP-14 was stained with 
MMP-14 mAbs followed by AF488-conjugated secondary mAbs. Shown are a 
representative DIC image of formed thrombi and representative fluorescence images 
of MMP-1, -2, -9 and -14 against an IgG background. Data are representative of 
three independent experiments. Scale bar = 50 μm. 
Figure 4. Platelet-derived MMP activity, which is released within minutes, is 
highest after GPVI-stimulation and predominantly membrane-associated. 
Human resting washed platelets (1 x 109/mL) were activated as indicated and MMP 
activity was measured with OmniMMP substrate or selective MMP-2 EnSens 
substrate. (A) Bar graph shows OmniMMP activity after 10 min stimulation of 
platelets with different agonists. (B) Bar graph of MMP activity of the membrane 
bound and secreted fraction of unstimulated or convulxin-activated platelets. (C) 
Slope of OmniMMP activity in time (FU/min) of unstimulated and convulxin-activated 
platelets (n=5); *P<0.05. (D) Slope of MMP-2 activity in time (FU/min) of unstimulated 
and convulxin-activated platelets (n=3) with(out) MMP-2 inhibitor (n=1). Data are 
mean ± SEM.  
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Figure 5. MMP-dependent collagen degradation is localized at the site of the 
thrombus and is redundantly regulated by MMPs but not platelet α-granule 
release. Human or murine blood was incubated with AF647-αGPIbα mAb to label 
platelets and perfused over a combined surface of immobilized Horm and DQ 
collagen at a shear rate of 1000 s-1 for 4 min. Formed thrombi were post-incubated 
with HEPES buffer containing 2-MeSADP with(out) phenanthroline or MMP-specific 
inhibitors. MMP activity was visualized as fluorescence signal by confocal 
microscopy. (A, C) Representative fluorescence profiles and images taken 1.5 h after 
thrombus formation. White dotted line indicates area of the fluorescence profile. (B) 
Bar graph expresses DQ collagen fluorescence as the percentage of collagen 
degradation in the presence of general and selective MMP-specific inhibitors 
compared to corresponding vehicle controls. (C) Representative fluorescence profiles 
and images of human and murine DQ collagen and AF647-αGPIbα taken 1.5 h after 
thrombus formation in presence of thrombin. (D) Bar graph expresses DQ collagen 
degradation for Mmp2, Mmp9 or Nbeal2 deficient murine blood or matched wild 
types. Scale bar = 30 μm, data are mean ± SEM (n=4-9); *P<0.05, **P<0.01, 
***P<0.001. 
Figure 6. Thrombi degrade underlying collagen fibers in a time-dependent 
manner. Human whole blood was perfused over immobilized Horm collagen at a 
shear rate of 1000 s-1 for 4 min. Formed thrombi were rinsed and incubated in 
HEPES buffer containing 2-MeSADP. At indicated time points, thrombi were fixed 
and prepared for SEM. (A) Representative SEM pictures of Horm collagen coating 
before thrombus formation and of formed thrombi on collagen at T= 0, 2, 4, 7 and 17 
h. (B) Insets of indicated squares in (A). Arrows indicate partly degraded collagen 
fibers. Representative SEM images of 9 experiments are depicted. Scale bar = 10 
μm. 
 
 
 
Su
rfa
ce
 a
re
a 
co
ve
ra
ge
(%
 o
f v
eh
ic
le
)
Phase contrast
AF647-annexin A5
FITC-αCD62P mAb
Vehicle MMP-1/8 inh. MMP-2 inh. MMP-9 inh. MMP-14 inh.
*
**
*
**
Vehicle MMP-2 inh. MMP-9 inh.MMP-1/8 inh. MMP-14 inh.
Ph
as
e 
co
nt
ra
st
A
B
AF
64
7-
an
ne
xi
n 
A5
FI
TC
-α
CD
62
P 
m
A
b
0
100
200
50
150
250
* * **
*
*
*
**
0
50
100
150
200
Mmp+/+ Mmp2-/- Mmp3-/- Mmp9-/-
Su
rfa
ce
 a
re
a 
co
ve
ra
ge
(%
 o
f W
T)
Phase contrast
AF647-annexin A5
FITC-αCD62P mAb
* *
C
*
*
Figure 1
DM
SO
 co
ntr
ol
MM
P-9
 in
h.
MM
P-1
4 i
nh
. 
MM
P-9
 + 
-14
 in
h.
0
500
1000
1500
In
te
gr
at
ed
  f
ea
tu
re
 s
ize
  (
μ
m
2 )
H 2
O c
on
tro
l
MM
P-1
/8 
inh
.
MM
P-2
 in
h.
*
**
*
Figure 2
DIC
IgG
PE-αMMP-2
FITC-αMMP-9 AF488-αMMP-14
PE-αMMP-1
Figure 3
05
10
15
20
M
M
P 
ac
ti
vi
ty
 
(µ
g/
m
l b
ac
te
ri
al
 c
ol
la
ge
na
se
)
Un
sti
m
ula
te
d
Th
ro
m
bin AD
P
Th
ap
sig
ar
gin
Co
nv
ulx
in 
(Cv
x)
Cv
x +
 th
ro
m
bin
Io
no
m
yc
in
Cv
x +
 ph
en
an
th
ro
lin
e
Un
sti
m
ula
te
d Cv
x
Membrane-bound
Released
*
*
*
*
A B
0
5
10
15
20
M
M
P 
ac
ti
vi
ty
 
(µ
g/
m
l b
ac
te
ri
al
 c
ol
la
ge
na
se
)
15 30 45
-0.5
0.0
0.5
1.0
1.5
2.0 Cvx
Unstimulated
Cvx + MMP-2 inh. III
Time (min)
M
M
P-
2 
ac
tiv
ity
 sl
op
e 
 (F
U
/m
in
)
0 20 40 60
0
10
20
30
40
Time (min)
M
M
P 
ac
tiv
ity
 sl
op
e 
 (F
U
/m
in
)
Unstimulated
Cvx
C D
Figure 4
Fl
uo
re
sc
en
ce
 
in
te
ns
it
y 
(A
U
)
0
50
100
150
0
50
100
150
Fl
uo
re
sc
en
ce
 
in
te
ns
it
y 
(A
U
)
+ Vehicle DQ collagen
AF647-αGP1β 100
75
50
25
0D
eg
ra
da
ti
on
 (%
 o
f c
on
tr
ol
)
Ve
hic
le
Ph
en
an
tro
lin
e
MM
P-1
/8 
inh
.
M
M
P-
2 i
nh
.
MM
P-9
 in
h.
A B
MM
P-1
4 i
nh
.
**
*
*
*
*
0
25 50 75 100
0 25 50 75 100
0
50
100
150
0
50
100
150
Fl
uo
re
sc
en
ce
 
in
te
ns
it
y 
(A
U
)
Fl
uo
re
sc
en
ce
 
in
te
ns
it
y 
 (A
U
)
Distance (µm)
Murine, + thrombin
Human, + thrombinC D
WT
M
m
p2
-/-
M
m
p9
-/-
Nb
ea
l2
-/-
D
eg
ra
da
ti
on
 (%
 o
f W
T)
*** ***
0
100
50
25
75
125
+ Phenantroline
Figure 5
Coating T=0 h T=2 h
T=4 h T=7 h T=17 h
A
B T=4 h T=7 h T=17 h
Figure 6
1 
 
Material and methods 
 
Reagents. 1,10-Phenanthroline monohydrate, carbonyl cyanide m-chlorophenyl 
hydrazone (CCCP) and collagenase derived from Clostridium histolyticum were from 
Sigma-Aldrich (St. Louis, Missouri, USA). H-Phe-Pro-Arg chloromethyl ketone 
(PPACK), FN439, MMP-2 inhibitor I and MMP-9 inhibitor I were from Calbiochem (La 
Jolla, California, USA). MT1-MMP inhibitor (NSC-405020) was purchased from Merck 
KGaA (Darmstadt, Germany). Leupeptin hemisulphate (Ac-Leu-Leu-Arg-al 
hemisulphate) and ionomycin were obtained from VWR International (Radnor, 
Pennsylvania, USA). The glycoprotein VI agonist, convulxin came from Stago BNL 
(Leiden, The Netherlands). Human thrombin was obtained from Enzyme Research 
Laboratories (Leiden, The Netherlands). Thapsigargin was purchased from Santa 
Cruz Biotechnology, Inc (Dallas, Texas, USA) and 2-methylthioADP (2-MeSADP) 
from Bioconnect (Huissen, The Netherlands). Horm collagen came from Nycomed 
(Munich, Germany). Annexin A5 labeled with Alexa Fluor (AF)-647 was obtained from 
Molecular Probes (Leiden, The Netherlands). Fluorescein isothiocyanate (FITC)-
conjugated rat anti-mouse P-selectin (CD62P) monoclonal antibody (mAb) was from 
Emfret Analytics (Würzburg, Germany). AF647 goat anti-mouse IgG1, dye-quenched 
(DQ) collagen (type I collagen from bovine skin, fluorescein-conjugated) and DQ 
gelatin (from pig skin, fluorescein-conjugated) were from Invitrogen (Carlsbad, 
California, USA). AF647-αGPIbα human mAb was from MBL International (Woburn, 
Massachusetts, USA). Human MMP-1 phycoerythrin (PE)-conjugated mAb (clone 
36607), human MMP-2 PE-conjugated mAb (clone 1A10), human MMP-9 
fluorescein-conjugated mAb (clone 56129), human MMP-14/MT1-MMP mAb (clone 
#5H2) and IgG isotype control PE-conjugated Ab (IC002P) were obtained from R&D 
Systems (Minneapolis, Minnesota, USA). Human IgG1 isotype control (26-787-
275125) was obtained from GenWay Biotech (San Diego, California, USA). The 
OmniMMP substrate was purchased from Enzo Life Sciences (Anvers, Belgium) and 
EnSens MMP-2 activity detection kit from Enzium (McNeil, Philadelphia, USA). 
 
Blood collection from healthy volunteers and mice. Human blood was drawn 
from healthy volunteers after full informed consent according to the declaration of 
Helsinki. The volunteers were free from antithrombotic medication for at least 2 
weeks. The blood was collected into 10% 129 mM trisodium citrate for the 
preparation of platelet-free plasma, 17% acid-citrate-dextrose (80 mM trisodium 
citrate, 52 mM citric acid, 183 mM D-glucose) for the isolation of washed platelets or 
40 μM PPACK and 40 U/mL fragmin for flow perfusion experiments.  
Mmp2-/- mice were generated as described1 and bred against a C57BL/6 
background. Mmp13-/- mice2 were provided by Drs. M. Byrne and S. Krane (Center 
for Immunology and Inflammatory Diseases and Division of Rheumatology, Allergy 
and Immunology, Massachusetts General Hospital and Harvard Medical School, 
Charlestown, Massachusetts, USA) and bred against a C57BL/6 background. Mmp-
3-/- and Mmp9-/- mice3,4 were bred against a B10.RIII and CD1 background, 
2 
 
respectively. Nbeal2-/- mice were bred against a C57BL/6N background as 
described.5 Wild-type littermate mice matching genetic background, age and sex 
were obtained from the host institutions and used as controls. Mice were 
anesthetized by a subcutaneous injection of 0.1 mg/g body weight ketamine and 0.02 
mg/g body weight xylazine and bled retro-orbitally. Mouse blood was collected into 
10% 129 mM trisodium citrate and 5 U/mL heparin. Platelet counts were in the 
normal range for all mice. Animal experiments were approved by the research ethics 
committees of Maastricht University, The Netherlands.  
  
Contribution of MMPs to real-time thrombus formation under flow. Flow 
perfusion experiments were performed with anticoagulated whole blood from mice 
deficient in MMP-2, -3 or -9 with blood from healthy volunteers. Prior to the 
experiment murine blood was recalcified with 7.5 mM CaCl2 and 3.75 mM MgCl2, to 
obtain physiological (millimolar) concentrations of Ca2+ and Mg2+, in the presence of 
40 μM PPACK. Human blood, already containing physiological Ca2+ and Mg2+ levels, 
was pre-incubated for 10 min at 37 °C with selective MMP inhibitors or respective 
vehicle: FN439 (MMP-1/8 inhibitor), MMP-2 inhibitor I (MMP-2 inhibitor), MMP-9 
inhibitor I (MMP-9 inhibitor) and/or NSC-405020 (MMP-14 inhibitor). Dose-response 
experiments revealed the optimal inhibitory/stimulatory effect of MMP-1/8 inhibitor at 
5 µM, of MMP-2 inhibitor at 10 µM, of MMP-9 inhibitor at 50 nM and of MMP-14 
inhibitor at 100 µM (data not shown). Murine and human blood was perfused over a 
collagen-coated coverslip that was mounted in a parallel-plate flow chamber at a 
shear rate of 1000 s-1 for 4 min, as described.6 Coverslips with murine thrombi were 
examined for surface coverage with an inverted microscope (Nikon Diaphot 22, 
Nikon; Tokyo, Japan). P-selectin expression (anti-CD62P) and phosphatidylserine 
(PS) exposure (annexin A5 binding) were assessed with a Bio-Rad 2100 multiphoton 
microscopic system (Carl Zeiss; Jena, Germany), as described.6, 7 Coverslips with 
human thrombi were examined for the same parameters using a single-photon, 
LSM7 Live line-scanning confocal system from Carl Zeiss (Oberkochen, Germany). 
Excitation was at 488 nm and emission between 540 to 625 nm. Images were taking 
with a 60x/1.4 NA oil emersion objective. Analysis of confocal images was performed 
with ImagePro/LaserPix software (Media Cybernetics; Silver Spring, Maryland, USA). 
Thrombus sizes was investigated as integrated feature size and was calculated as 
described previously.8 
 
Localization of MMP family members on thrombus surface. Thrombi were formed 
with blood from healthy volunteers as described above and were devoid of 
leukocytes (CD45). Coverslips with thrombi were post-stained with PE-conjugated 
mAbs against MMP-1, -2, or -9 (1:50 v/v in HEPES pH 7.45) for 20 min. Alternatively, 
αMMP-14 (MT1-MMP) (1 μg/mL) was added for 10 min, followed by AF647 goat anti-
mouse IgG1 (4 μg/mL) for 20 min. All mAbs were titrated in preliminary experiments 
and mouse IgG1 PE-conjugated antibody or human purified IgG served as a control. 
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Microscopic images were taken with a LSM7 Live line-scanning confocal system from 
Carl Zeiss, as described above. 
 
Fluorescence measurements of platelet-derived MMP activity. Human platelet-
free plasma and washed platelets were obtained, as described.9 Platelets were 
diluted to 2 x 109/mL and activated for 15 minutes with thrombin (8 nM), convulxin 
(Cvx, 0.1 µg/mL), ionomycin (20 µM), thapsigargin (0.5 µM) or 2-MeSADP (40 µM). 
Where indicated, the general MMP inhibitor phenanthroline (2 mM) was added 
immediately after platelet activation. Control experiments indicated that a lower 
concentration phenanthroline (100 µM) was similarly effective. OmniMMP substrate 
(40 µM) was added 1:1 v/v to the (activated) platelet sample in a 96-well plate. 
Fluorescence was measured in a Spectra max M2 plate reader (Molecular Devices; 
Sunnyval, California, USA) at 405 nm for 10 h at 37 °C. Bacterial collagenase was 
used as a positive control. MMP activity was determined by the maximal slope of the 
fluorescence signal (between T=0-1.5 h) and normalized to the bacterial collagenase 
activity. To determine membrane-bound MMP activity, activated platelets were 
centrifuged at 2240 g for 2 min. Both membrane-bound and supernatant fractions 
(i.e. the platelet releasate) were collected and used immediately. 
To perform kinetic measurements, platelets were activated with Cvx (1 µg/ml) 
plus thrombin (25 nM) for 0, 1, 2, 5, 10, 30 or 60 minutes and directly mixed with 
CCCP (100 µg/ml) to stop all ATP-dependent processes in platelets, such as platelet 
secretion. OmniMMP activity was then measured for 10 minutes as described above. 
Alternatively, a highly sensitive and specific cell-based MMP-2 activity assay was 
used according to manufacturer’s conditions. In brief, washed platelets (1 x 109/ml) 
were activated with Cvx (1 µg/ml) plus thrombin (25 nM) for 2 minutes and then 
mixed with Ensense MMP-2 detection mix. Fluorescent signal was detected with a 
LSM7 Live line-scanning non-confocal system from Carl Zeiss (Oberkochen, 
Germany). MMP-2 activity over time was determined by measuring the average pixel 
intensity per microscopic image and subsequent calculation of the first derivative. 
 
Collagen matrix-degrading potential of thrombus-derived MMPs. Glass 
coverslips were coated for 60 min with a mixed 10 µl spot of DQ collagen (25 µg/mL) 
and Horm collagen (50 µg/mL). After coating, the coverslips were blocked, rinsed and 
mounted into a parallel plate flow chamber. Thrombi were formed with blood from 
healthy volunteers as described above and were devoid of leukocytes (CD45). 
Specific MMP inhibitors FN439 (5 µM), MMP-2 inhibitor I (10 µM), MMP-9 inhibitor I 
(50 nM), NSC-405020 (100 µM) or phenanthroline (1 mM, with 100 µM yielding the 
same results) were added to HEPES buffer (including 5 mM CaCl2, 5 mM MgCl2, 10 
µM 2-MeSADP and, optionally, 25 nM human thrombin) and incubated with the pre-
formed thrombi as indicated. Alternatively, thrombi were made with Mmp-2-/-, -9-/- or 
Nbeal2-/- blood during 4 min whole blood perfusion at 1000 s-1 and carefully rinsed 
with HEPES buffer (including 5 mM CaCl2, 5 mM MgCl2, 10 µM 2-MeSADP and 25 
nM human thrombin) to remove unbound blood components. Human thrombin (25 
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nM) and 2-MeSADP (10 µM) was added to the incubation buffer to prevent thrombus 
embolization during the incubation time. After 1.5 h of incubation, DQ collagen 
degradation was visualized using a single-photon, LSM7 Live line-scanning confocal 
system from Carl Zeiss (Oberkochen, Germany) at an excitation wavelength of 488 
nm and emission wavelength of 540 to 625 nm. 
 
Imaging of thrombus-dependent collagen matrix degradation by scanning 
electron microscopy. Thrombi were formed with blood from healthy volunteers as 
described above, rinsed to remove unbound blood components and then incubated 
at 37 °C with HEPES buffer supplemented with the antibiotics penicillin plus 
streptomycin. Where indicated phenanthroline (1 mM) was added to the HEPES 
buffer. At time point 0, 2, 4, 7 and 17 h thrombus- and collagen containing coverslips 
were carefully removed from the flow chamber and gently washed in HEPES buffer. 
Samples were fixed overnight with 2.5% glutaraldehyde diluted in 0.1 M phosphate 
buffer (pH 7.4) at 4 °C. After rinsing with 0.1 M phosphate buffer, followed by 
dehydration in graded concentrations of ethanol, samples were critical point dried, 
mounted with silver paint on specimen stubs and coated with gold.10 Thrombi on 
(partly degraded) collagen fibers were visualized with a scanning electron 
microscope (Philips XL 30, Eindhoven, The Netherlands) at 10 kV. 
 
Statistics. Groups were compared using the Mann-Whitney U-test or the 
independent samples t-test, as appropriate (Graphpad v5.0; La Jolla, California, 
USA). P<0.05 was considered statistically significant. 
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Supplemental methods 
Reagents. Poly-L-Lysine, 1,10-Phenanthroline monohydrate and saponin were from 
Sigma-Aldrich (St. Louis, Missouri, USA). The glycoprotein VI agonist, convulxin 
came from Stago BNL (Leiden, The Netherlands). Human thrombin was obtained 
from Enzyme Research Laboratories (Leiden, The Netherlands). 2-methylthioADP (2-
MeSADP) from Bioconnect (Huissen, The Netherlands). Horm collagen came from 
Nycomed (Munich, Germany). Human MMP-1 phycoerythrin (PE) conjugated mAb 
(clone 36607), human MMP-2 PE conjugated mAb (clone 1A10), human MMP-9 
fluorescein conjugated mAb (clone 56129), human MMP-14/MT1-MMP mAb (clone 
#5H2) and IgG isotype control PE conjugated Ab (IC002P) were obtained from R&D 
Systems (Minneapolis, Minnesota, USA). Human IgG1 isotype control (26-787-
275125) was obtained from GenWay Biotech (San Diego, California, USA). DiOC6 
was purchased from AnaSpec (Waddinxveen, The Netherlands). Imsol Mount was 
from immunologic (Duiven, The Netherlands). 
 
Subcellular MMP localization and MMP-9 binding 
Human blood was drawn from healthy volunteers after full informed consent 
according to the declaration of Helsinki. The blood was collected in 17% acide-
citrate-dextrose (80 mM trisodium citrate, 52 mM citric acid, 183 mM D-glucose), after 
which washed platelets were prepared as described.1 Resting or convulxin (1 µg/ml, 
10 min) activated platelets (1 x 108/mL) were fixed with phosphate buffered saline 
(PBS) + 4% formaldehyde for 20 minutes and washed twice in PBS + 0.2% bovine 
serum albumin (BSA). Platelets were permeabilized in 0.1% saponin in PBS + 0.2% 
BSA for 30 minutes and all consequent steps also contained 0.1% saponin. Non-
specific sites were blocked with 2% BSA and 1 µg/ml non-specific IgG for 1h after 
which platelets were washed. Platelet samples were then stained overnight with PE- 
or FITC conjugated mAbs against MMP-1, -2, or -9 (1:20 v/v in PBS + 2% BSA) at 4 
°C. Alternatively, platelet samples were incubated overnight with αMMP-14 (MT1-
MMP) (5 μg/mL) at 4 °C, washed with PBS and then stained with AF647 goat anti-
mouse IgG1 (4 μg/mL) for 1 h. To examine colocalization with the alpha-granule 
constituent P-selectin, all samples were again washed and stained with AF647-
αCD62P (1:20). Samples were spun down at 250 g for 10min on poly-l-lysine coated 
coverslips (0.01%) and subsequently mounted using Imsol Mount for microscopic 
examination using the EVOS® Cell Imaging System. Colocalization of MMP family 
members with P-selectin was determined by using the “Colocalization Threshold” 
analysis option in Fiji v.1.48g software.2 Herein, a standardized method was used to 
set a threshold to correct for background signal across images obtained with the 
different antibodies. 
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Thrombogenicity of thrombus-degraded collagen fibers.  
Human blood was perfused over a collagen-coated coverslip that was mounted in a 
parallel-plate flow chamber at a shear rate of 1000 s-1 for 4 min, as described.3 
Formed thrombi were rinsed with HEPES buffer to remove unbound blood 
components and then incubated overnight at 37 °C with HEPES buffer supplemented 
with 5 mM CaCl2, 5 mM MgCl2, 10 µM 2-MeSADP, 25 nM human thrombin and 
penicillin plus streptomycin. Where indicated phenanthroline (1 mM) was added to 
the HEPES buffer. After overnight incubation thrombi were lysed with 0.1% triton X-
100 to enable microscopic visualization of the underlying collagen. Microscopic 
images from >10 different fields per sample were collected with an inverted 
microscope (Nikon Diaphot 22, Nikon; Tokyo, Japan). The mean visible collagen fiber 
length before and after 24 h incubation was determined in pixels using Metamorph 
software (Molecular Devices; Sunnyvale, California, USA) and compared as an 
estimate of the percentage of collagen degradation. 
 Alternatively, after overnight incubation the flow chamber was rinsed with 
HEPES buffer to remove unbound cellular components. Triton X-100 was not used in 
this case. After rinsing, freshly drawn DiOC6-labeled blood from the same donor was 
perfused through the chamber for 4 minutes at 1000 s-1. Adhesion of DiOC6-labeled 
platelets was visualized using a single-photon, LSM7 Live line-scanning confocal 
system from Carl Zeiss (Oberkochen, Germany). 
 
 3 
Supplemental results 
 
Suppl. figure I. Subcellular localization of MMP-1, -2 and -14 in unstimulated and 
convulxin-activated platelets. Unstimulated or convulxin-activated platelets were fixed, 
permeabilized and stained for MMP family members in combination with P-selectin. Shown 
are representative microscopic images of (A) resting platelets and (B) convulxin-activated 
platelets stained for MMP-1 (PE-αMMP-1), MMP-2 (PE-αMMP-2), MMP-9 (FITC-αMMP-9) or 
MMP-14 (αMMP-14+AF488-IgG1); and P-selectin (AF647-αCD62P) with corresponding 
overlay. Note the granular distribution of MMP-1 and -2 in unstimulated platelets, distinctive 
from the fluorescent signal obtained with AF647-αCD62P. n=3, scale bar = 5 μm. 
 
Suppl. figure II. Quantitative 
determination of MMP-1, -2 and -14 
colocalization with the alpha-granule 
marker P-selectin. Washed human 
platelets were stained for MMP-1, -2 and -14 
as described for suppl. fig. I. Shown is a bar 
graph with Pearson’s correlation co-
efficients determined by thresholding 
microscopic images >50 platelets and Fiji 
software. Data are mean ± SEM (n=3).  
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Suppl. figure III. MMP-9 is not present in 
platelets but binds to the surface of 
activated platelets in a plasma 
environment. Washed human platelets 
were activated in HEPES buffer or plasma 
for 5 min with convulxin. Platelets were then 
washed, fixed, permeabilized and stained for 
MMP-9. (A) Bar graph represents the 
analysis of MMP-9 fluorescence normalized 
to surface area coverage in the phase 
contrast image. (B) Representative 
fluorescence and phase contrast images of a single activated platelet. Scale bar = 5 μm, 
data are mean ± SEM (n=3); **p<0.01. 
 
 
 
Suppl. figure IV. Thrombus-mediated collagen 
degradation is MMP-dependent. Human blood was 
perfused over immobilized Horm collagen at a shear rate of 
1000 s-1 for 4 min. Formed thrombi were post-incubated with 
HEPES buffer with(out) the MMP inhibitor phenanthroline. At 
indicated time points, thrombi were lysed with 0.1% triton X-
100 to enable microscopic visualization of the underlying 
collagen. Shown is the effect of phenanthroline (24 h) on 
collagen fiber length normalized to vehicle T=0. Data are 
mean ± SEM (n=3); ***p<0.001. 
 
 
 
Suppl. figure V. Thrombus-mediated collagen degradation 
restricts further thrombus formation. Human thrombi were 
formed as described for suppl. fig. IV and post-incubated with 
HEPES buffer at 37 °C. After overnight incubation the flow 
chamber was rinsed with HEPES buffer. Freshly drawn DiOC6-
labeled blood was perfused through the chamber for 4 min at 1000 
s-1. Bar graph represents the analysis of surface area coverage of 
DiOC6-labeled platelets. Data are mean ± SEM (n=3); ***p<0.001. 
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Suppl. table 1 Literature on whether MMP-9 is present in platelets 
       
Method Sample 
concentration 
mentioned 
Species Platelet source Resting / activated Present in / 
derived from 
platelets 
Ref. 
Activity assay No Human Supernatant Resting & activated No 
4
 
  No Human Lysate & supernatant Activated No 
5
  
CZE Yes Human Lysate Resting Yes 
6
 
Electron microscopy      
      mAb N/A Human Washed platelets Resting & activated Yes 
6
 
      pAb N/A Human Washed platelets Resting Yes 
7
 
ELISA No Human Lysate & supernatant Resting & activated No 
8
 
  No Human Lysate & supernatant Activated No 
5
 
  No Human Supernatant Resting & activated No 
4
 
  No Human Lysate Resting & activated No 
9
 
Flow cytometry       
      pAb; non perm. N/A Human Washed platelets Activated Yes 
10
 
      mAb; non perm. N/A Human Washed platelets Resting & activated Yes 
11
 
      perm. & non perm. N/A Human PRP Resting Yes 
12
 
Immunofluorescence      
      perm. N/A Human PRP Resting Yes 
13
 
      mAb; non perm. N/A Human Washed platelets Resting No 
8
 
      mAb; perm. N/A Human Washed platelets Resting No 
4
 
Luminex multiplex No Human Supernatant Resting & activated Yes 
14
 
Proteomics N/A Human Lysate Resting No 
15
 
  N/A Human Lysate Resting No 
16
 
  N/A Human, rat Lysate Resting No 
17
 
  N/A Human Lysate Activated No 
18
 
  N/A Mouse Lysate Resting No 
19
 
  N/A Human Lysate Activated No 
20
 
  N/A Human Lysate Resting No 
21
 
  N/A Human Lysate Activated No 
22
 
RNA sequencing No Human Lysate Resting No 
23
 
  Yes Human Lysate Resting Yes 
9
 
  Yes Human, mouse Lysate Resting No 
24
 
RT-PCR No Human Lysate Resting No 
25
 
  Yes Human Lysate Resting & activated No 
5
 
  Yes Human Lysate Resting Yes 
9
 
Western blot       
      pAb Yes Human Lysate Resting Yes 
10
 
      mAb Yes Human Lysate & supernatant Resting & activated No 
25
 
      pAb No Human Supernatant Activated No 
5
 
Zymography Yes Human Lysate Resting Yes 
26
 
  No Human Lysate Resting No 
23
 
  No Human Lysate Resting No 
27
 
 Yes Human Lysate & supernatant Resting Yes 
10
 
  Yes Human Lysate & supernatant Resting & activated No 
25
 
  No Human Supernatant Activated No 
5
 
  Yes Human Supernatant Resting Yes 
28
 
  Yes Human Supernatant Resting & activated Yes 
29
 
 
Abbreviations: CZE, capillary zone electrophoresis; RT-PCR, reverse transcription-polymerase chain reaction; mAb, monoclonal 
antibody; pAb, polyclonal antibody; N/A, not applicable; non perm., non permeabilized; perm., permeabilized; PRP, platelet rich 
plasma 
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